KPCIRCKwatra Precision Cancer Institute and Research Centre
I amHow can we help?DoctorsPatientsHospitalsIndustryResearch
EnquireSubmit a caseRequest consultationPartner with usLab partnershipCollaborate
Menu
KPCIRCKwatra Precision Cancer Institute and Research Centre

How can KPCIRC help you?

Start an enquirySubmit a Case / ReportRequest a ConsultationPartner With KPCIRCDiscuss a Laboratory PartnershipPropose a Collaboration

Find a DoctorContact011 4353 3607
A researcher analysing a circular genome plot on a computer screen.

POAS · Precision Oncology Analysis Service

A genomic report is not the final answer.

A molecular report tells you what was detected. The harder question is what those findings mean for this patient, this cancer and the clinical question under consideration.

Submit a Report for AssessmentDiscuss POAS With Our Team

The Precision Oncology Analysis Service (POAS) is a structured interpretation service for existing NGS, genomic and relevant molecular reports. It organises molecular findings, evidence strength, therapeutic context, clinical-trial opportunities, treatment-access information and unresolved questions into a report for clinician-led assessment.

Core principle

A detected alteration is not automatically actionable. Clinical significance depends on tumour type, disease setting, assay quality, evidence strength, treatment context and the patient’s circumstances.

Six analytical layers, each with a defined job

The six layers are complementary, not six independent treatment recommenders. All six are considered in every POAS workflow; the depth possible in each layer depends on the submitted report, the clinical question and the quality of the available data.

  1. 01CloneTraceVariant distribution and tumour contentReads the reported variants against the specimen and technical context, so each finding is interpreted with the quality and tumour content of the sample in view.How CloneTrace works
  2. 02PhenoMapTumour biology and molecular contextPlaces selected alterations in the context of tumour biology: the pathways, biomarker classes and disease-specific evidence relevant to this cancer.How PhenoMap works
  3. 03ImmunoLensImmunotherapy-associated evidenceStructures immunotherapy-associated biomarkers with the assay and tumour context needed to interpret them responsibly.How ImmunoLens works
  4. 04SynerGXTherapeutic evidenceOrganises potentially relevant therapeutic associations by evidence strength, so options can be considered in order of how well they are supported in this cancer and setting.How SynerGX works
  5. 05TrialGraphClinical-trial intelligenceIdentifies potentially relevant clinical trials and organises their eligibility criteria against the information supplied, so the treating team knows exactly what to verify.How TrialGraph works
  6. 06AccessMatchTreatment-access contextAdds practical context about whether a therapy under discussion is approved, available and affordable in India, and which facts still need confirmation.How AccessMatch works

Read the full explanation of all six layers

How POAS works

From the moment a report arrives to the moment the treating clinician receives a structured output.

  1. Report submission

    The existing report and the clinical question arrive through the approved submission workflow.

  2. Completeness check

    Available materials are checked for adequacy. Gaps are flagged rather than silently assumed.

  3. Six-layer analysis

    The report is reviewed across all six layers, according to the available data, disease context and scope.

  4. Evidence integration

    Findings, evidence, hypotheses and missing information are synthesised and kept visibly distinct.

  5. Clinician-led review

    Relevant cases are routed through clinician review and, where agreed, the Molecular Tumour Board.

  6. Structured report

    Findings, evidence strength, options, trial and access context, and limitations are delivered to the treating clinician.

Clinical follow-through, including any treatment decision, remains within the patient’s care arrangement with the treating clinician.

Who POAS is for

  • Treating oncologists who already have an NGS or molecular report and need structured interpretation.
  • Hospitals and nursing homes that want to offer molecular report interpretation without building every analytical component internally.
  • Molecular laboratories seeking an interpretation or clinical-review pathway to complement their testing services.
  • Patients who already hold a relevant report and want to understand an appropriate clinical review pathway. Involvement of the treating clinician is encouraged.
A laboratory scientist in a cap and mask examining a sample under a microscope.

Reports that can be considered

  • Tissue-based molecular panels
  • Liquid-biopsy or ctDNA reports
  • Whole-exome (WES) or whole-genome (WGS) sequencing reports
  • Haematology and blood-cancer molecular panels
  • Other relevant molecular or genomic reports, subject to suitability and the clinical question

POAS interprets existing reports; a new test is not required just to request an interpretation. Further testing may be suggested for consideration if the supplied information cannot answer the clinical question, but that decision belongs to the treating clinician and patient.

What the POAS report is designed to contain

Molecular read

Alterations that may be relevant, and findings that may not be clinically meaningful in the supplied context.

Therapeutic evidence

Relevant associations with their evidence strength and the limitations of that evidence.

Trial intelligence

Potentially relevant trial protocols and the eligibility questions to verify.

Access context

Available information on regulatory status, indicative pricing or access mechanisms, with verification caveats.

Gaps and uncertainty

Unresolved variants, missing clinical information, assay limitations and further questions that may merit review.

Clinical review record

Documentation of the agreed review process and responsible sign-off, according to the finalised KPCIRC workflow.

Evidence resources

Depending on the case, sources may include OncoKB, CIViC, VICC, My Cancer Genome, JAX-CKB, COSMIC and Personalised Cancer Therapy, along with relevant guidelines, published research and trial registries. The exact sources used vary by report, biomarker and availability, and are stated in the report. Their inclusion does not imply endorsement or equal evidence strength across sources.

What POAS does not do

  • It does not replace the diagnostic laboratory or independently validate the original assay beyond the supplied information.
  • It does not automatically convert every detected variant into a treatment recommendation.
  • It does not guarantee drug response, clinical benefit, treatment access, trial eligibility or enrolment.
  • It does not replace the treating oncologist, the patient’s consent or any necessary multidisciplinary discussion.
  • It does not create a clinical prescription or independently determine the treatment plan.

Short explainers, in production

Frequently asked questions

Do I need to order a new genetic test before using POAS?

Not necessarily. POAS is designed to interpret existing NGS and relevant molecular reports. If the report lacks information needed to address the clinical question, the gap is identified for the treating clinician to consider.

Can POAS work with liquid-biopsy reports?

Liquid-biopsy and ctDNA reports can be considered. Interpretation depends on the assay, report details, tumour context, specimen characteristics and the question being asked.

Does a matched drug mean it will work?

No. An association or evidence-supported option does not establish that a treatment will work for an individual patient. Evidence strength, setting, limitations, patient factors and access all require review.

Can POAS help identify clinical trials?

The service can identify potentially relevant studies from the available information. Trial status, site availability and eligibility must be confirmed with the trial team.

How long does a POAS review take?

The expected timing is confirmed for each request, together with scope and fees, before the review proceeds.

How much does POAS cost?

Fees are confirmed for each request before the review proceeds. Use the POAS enquiry form to request a quote.

Enquiry

Discuss POAS with our team

Ask about report suitability, the review workflow, institutional use or pricing. To start a case, use Submit a Case / Report instead.

  • Fields marked * are required.
  • This form is not for emergencies or medical records.
  • Read how information is used in the Privacy Policy.
Report types you work with

No patient names, dates of birth, hospital numbers or report contents.

Illustrative POAS scenarios

Educational composite scenarios that explain possible workflows. They are not real KPCIRC patients, testimonials or outcomes.

All case studies